CA2356539A1 - Utilisation de composes 17-cetosteroides et de leurs derives, metabolites et precurseurs pour le traitement du paludisme et le traitement de la trypanosiomase africaine ou americaine - Google Patents

Utilisation de composes 17-cetosteroides et de leurs derives, metabolites et precurseurs pour le traitement du paludisme et le traitement de la trypanosiomase africaine ou americaine Download PDF

Info

Publication number
CA2356539A1
CA2356539A1 CA002356539A CA2356539A CA2356539A1 CA 2356539 A1 CA2356539 A1 CA 2356539A1 CA 002356539 A CA002356539 A CA 002356539A CA 2356539 A CA2356539 A CA 2356539A CA 2356539 A1 CA2356539 A1 CA 2356539A1
Authority
CA
Canada
Prior art keywords
compound
formula
alkyl
optionally substituted
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002356539A
Other languages
English (en)
Inventor
Clarence Nathaniel Ahlem
James Martin Frincke
Patrick T. Prendergast
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harbor Biosciences Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2356539A1 publication Critical patent/CA2356539A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C07J3/005—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom the carbon atom being part of a carboxylic function
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

L'invention concerne l'utilisation de composés 17-cétostéroïdes, ainsi que des dérivés, des métabolites et des précurseurs desdits composés, et des sels pharmaceutiquement acceptables de l'un quelconque de ces composés (ci-après appelés collectivement "composés de l'invention") destinés à traiter le paludisme et la trypanosiomase africaine ou américaine, ou à améliorer ou réduire un ou plusieurs symptômes associés à l'infection à Plasmodium ou à Trypanosoma. L'invention concerne également l'utilisation desdits composés pour le traitement ou la prévention d'un ou plusieurs types de parasites et/ou d'une ou plusieurs maladies causées par ces parasites, contre un ou plusieurs types de Mycoplasma et/ou une ou plusieurs maladies causées par ces mycoplasmes et/ou une ou plusieurs des indications ou infections suivantes: a) la leucoplasie chevelure, b) la candidose buccale, c) les ulcérations buccales (aphteuses, herpétiques, bactériennes), d) l'infection fongique à candida, e) le papillomavirus, f) le molluscum contagiosum, g) le carcinome buccal squameux, h) les lésions buccales dues à la maladie de Kaposi, i) la parodontite, j) la gingivite nécrosante, k) le zona bucco-facial; et 1) des rétrovvirus, ainsi que d'autres indications ou infections. Les composés de l'invention peuvent être également utilisés pour améliorer ou diminuer un ou plusieurs symptômes associés à l'une quelconque des infections ou maladies ci-décrites.
CA002356539A 1998-11-24 1999-11-24 Utilisation de composes 17-cetosteroides et de leurs derives, metabolites et precurseurs pour le traitement du paludisme et le traitement de la trypanosiomase africaine ou americaine Abandoned CA2356539A1 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US10992398P 1998-11-24 1998-11-24
US60/109,923 1998-11-24
US12408799P 1999-03-11 1999-03-11
US12605699P 1999-03-23 1999-03-23
US60/126,056 1999-03-23
US60/124,087 1999-03-23
PCT/US1999/028079 WO2000032201A2 (fr) 1998-11-24 1999-11-24 Utilisation de composes 17-cetosteroides et de leurs derives, metabolites et precurseurs pour le traitement du paludisme et le traitement de la trypanosiomase africaine ou americaine

Publications (1)

Publication Number Publication Date
CA2356539A1 true CA2356539A1 (fr) 2000-06-08

Family

ID=27380739

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002356539A Abandoned CA2356539A1 (fr) 1998-11-24 1999-11-24 Utilisation de composes 17-cetosteroides et de leurs derives, metabolites et precurseurs pour le traitement du paludisme et le traitement de la trypanosiomase africaine ou americaine

Country Status (13)

Country Link
EP (1) EP1135138A2 (fr)
JP (1) JP2002531407A (fr)
KR (2) KR20010101073A (fr)
CN (1) CN1348373A (fr)
AP (1) AP1584A (fr)
AU (2) AU776853B2 (fr)
BR (1) BR9915623A (fr)
CA (1) CA2356539A1 (fr)
HK (1) HK1043319A1 (fr)
IL (1) IL142941A0 (fr)
NZ (1) NZ511720A (fr)
OA (1) OA11715A (fr)
WO (1) WO2000032201A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070129282A1 (en) 1998-11-24 2007-06-07 Ahlem Clarence N Pharmaceutical treatments and compositions
US6667299B1 (en) 2000-03-16 2003-12-23 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical compositions and treatment methods
EP1223928A2 (fr) * 1999-07-08 2002-07-24 Patrick Thomas Prendergast Utilisation de flavones, de coumarines et de composes associes dans le traitement d'infections
EP1955700B9 (fr) 1999-09-30 2011-09-07 Harbor BioSciences, Inc. Traitement thérapeutique des maladies liées au récepteur androgène
US20050101581A1 (en) 2002-08-28 2005-05-12 Reading Christopher L. Therapeutic treatment methods 2
US7910755B2 (en) 2004-09-29 2011-03-22 Harbor Biosciences, Inc. Stem cell expansion and uses
US8217025B2 (en) 2006-11-17 2012-07-10 Harbor Therapeutics, Inc. Drug screening and treatment methods
KR100786126B1 (ko) * 2007-08-14 2007-12-18 주식회사 아바코 비접촉 방식에 의한 피절단물의 평탄도를 유지하는스크라이브 헤드 장치 및 그 스크라이브 방법

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL194728C (nl) * 1987-04-16 2003-01-07 Hollis Eden Pharmaceuticals Farmaceutisch preparaat geschikt voor de profylaxe of therapie van een retrovirale infectie of een complicatie of gevolg daarvan.
IL126623A0 (en) * 1996-04-17 1999-08-17 Prendergast Patrick T Pharmaceutical compositions and kits for dhea combined therapy
WO1998047516A1 (fr) * 1997-04-17 1998-10-29 Prendergast Patrick T Therapie combinee mettant en application des 17-cetosteroides et des inhibiteurs d'interleukine, ou interleukine-10 eventuellement avec des inhibiteurs d'interleukine

Also Published As

Publication number Publication date
HK1043319A1 (zh) 2002-09-13
IL142941A0 (en) 2002-04-21
KR20010101073A (ko) 2001-11-14
NZ511720A (en) 2002-12-20
WO2000032201A3 (fr) 2000-12-21
AP2001002182A0 (en) 2001-06-30
KR20070004149A (ko) 2007-01-05
AU776853B2 (en) 2004-09-23
OA11715A (en) 2005-03-14
BR9915623A (pt) 2001-08-14
AP1584A (en) 2006-03-01
JP2002531407A (ja) 2002-09-24
AU1745300A (en) 2000-06-19
AU2004237812B2 (en) 2007-11-29
CN1348373A (zh) 2002-05-08
AU2004237812A1 (en) 2005-01-13
WO2000032201A2 (fr) 2000-06-08
EP1135138A2 (fr) 2001-09-26

Similar Documents

Publication Publication Date Title
US7524835B2 (en) Tetrol steroids and esters
EP1223941B1 (fr) Traitements therapeutiques pour des deficiences en cellules sanguines par des steroides
AU2004237812B2 (en) Use of 17-ketosteroid compounds and derivatives, metabolites and precursors thereof in the treatment of malaria and the treatment of African and American trypanosomiasis
RU2295534C2 (ru) Полугидрат 16 альфа-бромо-3 бета-гидрокси-5 альфа-андростан-17-он, способ его получения, фармацевтические композиции, применение соединений
AU775614B2 (en) Use of 17-ketosteroid compounds and derivatives, metabolites and precursors thereof in the treatment of hepatitis C virus and other togaviruses
EP1422234A2 (fr) Steroides avec activité d'immunomodulation, surtout le hemihydrat du 16.alpha.-bromoepiandrosterone
CA2352387A1 (fr) Utilisation de composes 17-cetosteroides et de leurs derives, metabolites et precurseurs pour le traitement de la toxoplasmose ou de la cryptosporidiose
MXPA01005166A (en) Use of 17-ketosteroid compounds and derivatives, metabolites and precursors thereof in the treatment of malaria and the treatment of african and american trypanosomiasis
MXPA01005170A (en) Use of 17-ketosteroid compounds and derivatives, metabolites and precursors thereof in the treatment of hepatitis c virus and other togaviruses
ZA200103845B (en) Use of 17-ketosteroid compounds and derivatives, metabolites and precursors thereof in treatment of toxoplasmosis and in the treatment of cryptosporidiosis.

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued